Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed–Sternberg cells

Kopan R, Ilagan MX . The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216–233.

Radtke F, Fasnacht N, Macdonald HR . Notch signaling in the immune system. Immunity 2010; 32: 14–27.

Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B . Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398–3403.

Kochert K, Ullrich K, Kreher S, Aster JC, Kitagawa M, Johrens K et al. High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas. Oncogene 2011; 30: 1831–1840.

Jundt F, Acikgoz O, Kwon SH, Schwarzer R, Anagnostopoulos I, Wiesner B et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008; 22: 1587–1594.

Osipo C, Golde TE, Osborne BA, Miele LA . Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008; 88: 11–17.

Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed–Sternberg cells. Blood 1996; 87: 4340–4347.

Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961–2969.

Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003; 102: 1028–1034.

Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed–Sternberg cells. Blood 1999; 94: 3129–3134.

Emmerich F, Theurich S, Hummel M, Haeffker A, Vry MS, Dohner K et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells. J Pathol 2003; 201: 413–420.

Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C . Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed–Sternberg cells. Oncogene 1999; 18: 943–953.

Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin–Reed—Sternberg cells. Oncogene 2002; 21: 2493–2503.

Kuppers R . The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15–27.

Nonaka M, Horie R, Itoh K, Watanabe T, Yamamoto N, Yamaoka S . Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed–Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 2005; 24: 3976–3986.

Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed–Sternberg cells. Blood 2008; 111: 5118–5129.

Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196: 605–617.

Guo F, Sun A, Wang W, He J, Hou J, Zhou P et al. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009; 46: 2441–2448.

Wright CW, Rumble JM, Duckett C . CD30 activates both the canonical and alternative NF-kB pathways in anaplastic large cell lymphoma cells. J Biol Chem 2007; 282: 10252–10262.

Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008; 172: 510–520.

Bergmann M, Hart L, Lindsay M, Barnes PJ, Newton R . Ikappa B alpha degradation and nuclear factor-kappaB DNA binding are insufficient for interleukin-1beta and tumor necrosis factor-alpha-induced kappaB-dependent transcription. Requirement for an additional activation pathway. J Biol Chem 1998; 273: 6607–6610.

Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI . Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008; 111: 2220–2229.

Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006; 7: 207–215.

Scheidereit C . IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006; 25: 6685–6705.

Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A et al. Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769–776.

Aldinucci D, Poletto D, Gloghini A, Nanni P, Degan M, Perin T et al. Expression of functional interleukin-3 receptors on Hodgkin and Reed–Sternberg cells. Am J Pathol 2002; 160: 585–596.

Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed–Sternberg cells. J Exp Med 1999; 189: 1939–1946.

Schwarzer R, Kaiser M, Acikgoez O, Heider U, Mathas S, Preissner R et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia 2008; 22: 2273–2277.

Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113: 856–865.

Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001; 98: 2784–2790.

Oswald F, Liptay S, Adler G, Schmid RM . NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998; 18: 2077–2088.

Alison MR, Lim SM, Nicholson LJ . Cancer stem cells: problems for therapy? J Pathol 2011; 223: 147–161.

Deangelo DJSR, Silverman LB, Stock W, Attar EC, Fearen I et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006; 24: 357s.

Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50–58.